Headlines about Cidara Therapeutics (NASDAQ:CDTX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cidara Therapeutics earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.4844731770253 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several research analysts recently commented on the company. Cantor Fitzgerald set a $15.00 target price on Cidara Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, November 28th. HC Wainwright upped their price objective on Cidara Therapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. Zacks Investment Research raised Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $8.75 price objective for the company in a research report on Wednesday, October 25th. Finally, ValuEngine cut Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $13.03.
Cidara Therapeutics (CDTX) traded up $0.05 during trading hours on Friday, hitting $7.20. The stock had a trading volume of 65,929 shares, compared to its average volume of 68,916. The firm has a market cap of $146.73 and a PE ratio of -2.12. Cidara Therapeutics has a twelve month low of $5.60 and a twelve month high of $11.75. The company has a current ratio of 7.69, a quick ratio of 7.69 and a debt-to-equity ratio of 0.16.
In other news, major shareholder Target N. V. Biotech bought 60,000 shares of Cidara Therapeutics stock in a transaction dated Wednesday, November 15th. The stock was acquired at an average cost of $7.57 per share, with a total value of $454,200.00. Following the acquisition, the insider now owns 2,295,272 shares of the company’s stock, valued at $17,375,209.04. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 18.90% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/12/24/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-cidara-therapeutics-cdtx-stock-price.html.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.